Reducing Cardiovascular Risk With Effective Management Of LDL Cholesterol - A Round Table Discussion

Published: 18 December 2020

  • Views:

    Views Icon 79

  • Likes:

    Heart Icon 7
  • episode_image
    2m 29s
    Part 6 Chapter 6: Summary
    Kausik (Kosh) Ray, Lale Tokgözoğlu, Christie Ballantyne
Average (ratings)
No ratings
Your rating

Overview

This round table is designed to provide clinicians with a better understanding of the long-term CV risks of LDL-C exposure. In addition to reviewing the pathogenesis of atherosclerosis and assessing the long term implications of elevated LDL-C, this meeting will consider current guidance around controlling LDL-C, the challenges in achieving LDL-C targets, and evaluate how emerging strategies are contributing to LDL-C management.

 

Each chapter will comprise of a short presentation by the named medical expert followed by a panel discussion amongst all faculty.

This medical experts round table discussion was organised independently by Radcliffe Cardiology, work that was funded by Novartis. It is intended for healthcare professionals as medical educational material, and may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

Learning objectives

  • Outline the pathogenic nature and clinical risk of extended exposure to elevated LDL-C
  • Describe the clinical challenges in achieving guideline-based LDL-C goals
  • Compare and contrast LDL-C lowering therapies

More from this programme

Part 1

Chapter 1: Welcome and introductions

1 session
Chapter 1: Welcome and introductions Watch now

Part 2

Chapter 2: The role of long-term exposure to elevated LDL-C in the pathogenesis of atherosclerosis and clinical risk

1 session
Chapter 2: The role of long-term exposure to elevated LDL-C in the pathogenesis of atherosclerosis and clinical risk Watch now

Part 3

Chapter 3: Current approaches to controlling LDL-C – what do the guidelines say?

1 session
Chapter 3: Current approaches to controlling LDL-C – what do the guidelines say? Watch now

Part 4

Chapter 4: Challenges in achieving guideline-based LDL-C targets in the real world

1 session
Chapter 4: Challenges in achieving guideline-based LDL-C targets in the real world Watch now

Part 5

Chapter 5: Contemporary approaches to managing LDL-C and cardiovascular risk

1 session
Chapter 5: Contemporary approaches to managing LDL-C and cardiovascular risk Watch now

Part 6

Chapter 6: Summary

1 session
Chapter 6: Summary Watch now

Faculty Biographies

Kausik (Kosh) Ray

Kausik (Kosh) Ray

Professor of Public Health

Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials – Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease.

Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President-Elect of the European Atherosclerosis Society, also serving on the EAS Consensus…

View full profile